, Tracking Stock Market Picks
Enter Symbol:
Rating: CLVS
Hold $30

Clovis Oncology Inc (NASDAQ: CLVS) downgraded to Hold with price target $30 by WallachBeth

Tuesday,  Nov 17, 2015  8:25 AM ET by Lynn Gilbert

WallachBeth downgraded Clovis Oncology Inc (NASDAQ: CLVS) to Hold with price target
$30. Previously, WallachBeth rated Clovis Oncology Inc (NASDAQ: CLVS) to Buy with price target $115 on 06/15/2015, when the stock price was valued at $82.66.

Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy